Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterAccesswire • 02/14/24
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024Accesswire • 02/07/24
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024Accesswire • 01/23/24
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearAccesswire • 11/08/23
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023Accesswire • 11/07/23
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAccesswire • 10/26/23
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023Accesswire • 10/09/23
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023Accesswire • 09/27/23
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023Accesswire • 09/22/23
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian AuthorityAccesswire • 07/31/23
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAccesswire • 07/10/23
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketAccesswire • 06/13/23
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New DirectorAccesswire • 06/09/23